immunoglobulin (Ig) light chain. Neoformed germinal centers were colonized by a second, exceptionally abundant, HHV-8-infected PB population (CD138-, IgA-, IgM+) (Image 1D) ❚Image 1F❚. Double staining for HHV-8/CD20 showed only very rare double-stained cells ❚Image 2A❚. IHC revealed complete restriction of the HHV-8+, IgM+ PBs for the l immunoglobulin light chain ❚Image 2B❚. Epstein-Barr virus-encoded small RNA (EBER) was negative, excluding a germinotropic lymphoproliferative disorder. 11 The Ki-67 proliferation index was very high in PBs (>80%); cyclin D1 and CD34 were negative. The cells were Blimp-1/PRdm-1 weakly positive. 12 Double IHC staining for IgM and Myc revealed a variable and focal nuclear reactivity ❚Image 2C❚. Minimal apoptosis rate was demonstrated by phosphorylated histone H2AX (g-H2AX) staining. Fluorescence in situ hybridization (FISH) was negative for the detection of t(8;14)(q24.1;q32). Moreover, PBs had a diploid copy of chromosomes 8 and 14 ❚Image 2D❚. The HHV-8-infected B cells in CD are usually a small fraction of the cellularity. In our case, their large number was exceptional. Some authors have proposed the term microlymphomas to describe similar cases with possible transition to overt plasmablastic lymphoma. 4, 13 Myc expression, which has been shown to be upregulated by HHV-8 latent nuclear antigen (LANA), 14 has not been reported previously in this disease. The diploid status and the absence of Myc translocation by FISH examination were more consistent with a reactive or preneoplastic nature of the PBs, as reported by others with molecular data, such as Ig gene clonality. 15 It is thought that Myc is ubiquitously expressed in proliferating cells, where it controls cellular growth pathways via transcriptional and nontranscriptional mechanisms, including ribosome biogenesis, metabolism, the cell cycle, DNA replication, and telomere maintenance. 16 The upregulation of Myc, possibly via posttranscriptional stabilization by LANA, 14 may be the first of multiple steps toward the development of a frank malignancy (eg, plasmablastic lymphoma or primary effusion lymphoma). As many authors have shown, transcription factors associated with B cells (Pax5) or, more specifically, germinal center markers (Bcl6) are downregulated in normal and pathologic PBs, whereas the as an expression of bone marrow involvement by CD, 18 vanished after R-CHOP therapy. In conclusion, HHV-8+ PBs are highly proliferating cells with a minimal apoptosis rate and a momentary impossibility to differentiate into PCs.
In our "micromodel" IHC, double stainings confirmed a sort of compartmentalization between PBs and PCs. 4 The mature CD138+ PCs were attracted to the site of the CD lesions by chemotactic factors (interleukin-6), but they did not derive locally from a direct differentiation of PBs. Finally, our pattern of expression of Myc and the good clinical course of the patient should recommend caution in considering the presence of sheets of IgM-restricted plasmablasts outside of terminal differentiation program can be demonstrated with expression of Blimp-1, Xbp1, and Irf4/Mum1. However, PBs usually are completely CD138-, consistent with their transitional stage toward PCs. This is an important diagnostic key comparing other plasmablastic "proliferations," such as CD138+ plasmablastic lymphoma. Downregulated CD20 expression among the PBs was also interesting if we consider the role of successful rituximab therapy. 17 In our patient, 6 R-CHOP (rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone) cycles of chemotherapy resulted in a regression of all abdominal lesions. Moreover, a synchronous polyclonal plasmocytosis, follicles as a sufficient reason for a diagnosis of HHV-8+ large B-cell lymphoma. 1 
Technical Note
Buffered formalin-fixed, paraffin-embedded tissue was obtained from surgical specimens, and 3-µm sections were cut for H&E and special stains. IHC was performed after heat-mediated antigen retrieval on a DAKO autostainer (Glostrup, Denmark) using antibodies specific for CD20 (L26, DAKO), CD138 (B-B4, Serotec, Raleigh, NC), k immunoglobulin light chain (KR-10-21-F3, DAKO), l immunoglobulin light chain (N10/2, DAKO), IgM (polyclonal, DAKO), Pax5 (DAK-Pax5, DAKO), ki67 (MIB-1, DAKO), cyclin D1 (EP12, DAKO), CD34 (QBEnd 10, DAKO), and CD56 (C5.9, DAKO). Double staining for LANA-1 of HHV-8 (13B10, Ventana Medical Systems, Tucson, AZ) and CD20/CD138/l immunoglobulin light chain was performed using a Benchmark XT autostainer (Ventana Medical Systems). HHV-8 reactivity was tested with a 3,3'-diaminobenzidine (DAB) in chromogen solution, which yielded a brown color at the site of the target antigen, and counterstained with hematoxylin. CD20, CD138, and l had a red 3-amino-9-ethylcarbazole peroxidase substrate solution as a chromogen (cytoplasmic or membrane staining). Indirect IF was performed on paraffin-embedded tissue using fluorescein isothiocyanateconjugated IgM (polyclonal, DAKO) and IgA (polyclonal, DAKO) staining. Myc (1742-1, Y69, Epitomics, Burlingame, CA), Blimp-1 (6D3: sc-47732, Santa Cruz Biotechnology, Santa Cruz, CA), and g-H2AX (JBW301, Millipore, Billerica, MA) staining was performed in
